Literature DB >> 17928178

Effect of pharmaceutical excipients on aqueous stability of rabeprazole sodium.

Shan Ren1, Mi-Jin Park, Hongkee Sah, Beom-Jin Lee.   

Abstract

The chemical stability of a proton-pump inhibitor, rabeprazole sodium, was evaluated in simulated intestinal fluid (pH 6.8) containing various 'Generally Recognized As Safe (GRAS)'-listed excipients, including Brij 58, Poloxamer 188, Cremophor RH40, Gelucire 44/14 and PEG 6000. After incubation at 37 and 60 degrees C, the amounts of rabeprazole and its degradation product, thioether-rabeprazole, were quantitated by HPLC analysis. The main degradation product was separated and characterized by LC/MS. The degradation of rabeprazole followed first-order kinetics. In the absence of any excipients, the rate constants (k) obtained at 37 and 60 degrees C were 0.75 and 2.78h(-1), respectively. In contrast, the addition of excipients improved its stability. Among several excipients tested in this study, Brij 58 displayed the greatest stabilizing effect. For instance, at 37 and 60 degrees C, Brij 58 reduced the k values to 0.22 and 0.53h(-1), respectively. The stabilizing mechanisms of these hydrophilic polymeric excipients with optimal HLB values could be partially explained in terms of their solubilizing efficiency and micellar formation for thioether-rabeprazole. In conclusion, rabeprazole formulations that contain suitable excipients would improve its stability in the intestinal tract, thereby maximizing bioavailability.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17928178     DOI: 10.1016/j.ijpharm.2007.08.035

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  2 in total

1.  Rabeprazole sodium delayed-release multiparticulates: Effect of enteric coating layers on product performance.

Authors:  Rakesh N Tirpude; Prashant K Puranik
Journal:  J Adv Pharm Technol Res       Date:  2011-07

2.  Stability-indicating HPLC-DAD methods for determination of two binary mixtures: Rabeprazole sodium-mosapride citrate and rabeprazole sodium-itopride hydrochloride.

Authors:  Hamed M El-Fatatry; Mokhtar M Mabrouk; Ismail I Hewala; Ehab H Emam
Journal:  J Pharm Anal       Date:  2013-09-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.